
Claims:

Claim 1. A compound represented by Formula (I-A):



(I-A)

or a pharmaceutically acceptable salt or a tautomer thereof, wherein:

each ═ independently represents a single bond;

X is CH;

R^1 is H;

A is cycloalkyl, heterocyclyl, -CH_2-aryl, -CH_2-heteroaryl, aryl, or heteroaryl; wherein the aryl or heteroaryl is optionally substituted with aryl, heteroaryl, -Y^A-aryl, or –Y^A-heteroaryl; wherein Y^A is –O-, -C(O)-, -N(R^{A1})-, S(O)-, or –$S(O)_2$-; wherein R^{A1} is H or C_{1-6}alkyl;



wherein the -CH_2-aryl, -CH_2-heteroaryl, each aryl, and each heteroaryl are optionally substituted with halo;



L^1 is –C(O)-NR^{L1}–,wherein each R^{L1} is H; and

B is a fused bicyclic aryl, a fused bicyclic heteroaryl, aryl, heteroaryl, cycloalkyl, –CH_2-heterocyclyl, or heterocyclyl, wherein the aryl, heteroaryl, cycloalkyl, or heterocyclyl is optionally substituted with aryl, heteroaryl, -Y^B-aryl, –Y^B-heteroaryl, –Y^B-heterocyclyl, or cycloalkyl; wherein Y^B is –O-, -CH_2-, -C(O)-, -N(R^{B1})-, -S(O)-, or –$S(O)_2$-; wherein R^{B1} is H or C_{1-6}alkyl;

wherein the fused bicyclic aryl, the fused bicyclic heteroaryl, -CH_2-aryl, -CH_2-heteroaryl, each aryl, each heteroaryl, each cycloalkyl, –CH_2-heterocyclyl, and each heterocyclyl are optionally substituted with one or more substituents selected from the group consisting of alkyl, halo, haloalkyl, -CN, -N(R^{B2})$_2$, -OH, -O-alkyl, and oxo; wherein each R^{B2} is independently H or C_{1-6}alkyl;

wherein when A is optionally substituted phenyl or thiophenyl, and L^1 is –C(O)-NH–;

then B is not  or ;


wherein when A is phenyl, and L^1 is –C(O)-NH–; then B is not  or .







Claim 2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein A is cycloalkyl, heterocyclyl, -CH2-aryl or -CH2-heteroaryl.





Claim 3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt or tautomer thereof, wherein the aryl is substituted with halo.


Claim 4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt or tautomer thereof, wherein B is a fused bicyclic aryl.

Claim 5. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt or tautomer thereof, wherein B is a fused bicyclic heteroaryl.

Claim 6. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt or tautomer thereof, wherein B is selected from the group consisting of ,

, , , , , ,


, , , and .

Claim 7. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt or tautomer thereof, wherein B is .

Claim 8. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt or tautomer thereof, wherein B is aryl substituted with aryl or heteroaryl.

Claim 9. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt or tautomer thereof, wherein B is heteroaryl substituted with aryl or heteroaryl.

Claim 10. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt or tautomer thereof, wherein B is selected from the group consisting of



Claim 11. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt or tautomer thereof, wherein B is cycloalkyl optionally substituted with aryl, heteroaryl, -Y^B-aryl, –Y^B-heteroaryl.

Claim 12. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt or tautomer thereof, wherein B is –CH_2-heterocyclyl.




Claim 13. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt or tautomer thereof, wherein B is heterocyclyl optionally substituted with aryl or heteroaryl.





Claim 14. A compound, or a pharmaceutically acceptable salt or tautomer thereof, selected from the group consisting of





(a) Compound Nos. I-11 to I-44; I-47; I-49, I-50; I-52 to I-53; I-56 to I-59





Compound No.	Structure





Compound No.	Structure





Compound No.	Structure
I-11	 *Trans-Racemate* *(±)-trans*-4-phenyl-*N*-[3-(pyridin-3-yl)phenyl]pyrrolidine-3-carboxamide
I-12	 *Trans-Rac* *(±)-trans-N*-(isoquinolin-1-yl)-4-phenylpyrrolidine-3-carboxamide dihydrochloride
I-13	 *Trans-Rac*





Compound No.	Structure
	(±)-trans-N-(biphenyl-3-yl)-4-phenylpyrrolidine-3-carboxamide
I-14	 *Trans-Rac* *(±)-trans-N*-(isoquinolin-3-yl)-4-phenylpyrrolidine-3-carboxamide dihydrochloride
I-15	 *Trans-Rac* *(±)-trans-N*-(3-methylisoquinolin-5-yl)-4-phenylpyrrolidine-3-carboxamide dihydrochloride
I-16	 *Trans-Rac* *(±)-trans-N*-(naphthalen-1-yl)-4-phenylpyrrolidine-3-carboxamide hydrochloride
I-17	 *Trans-Rac*





Compound No.	Structure
	(±)-trans-4-phenyl-*N*-(quinolin-5-yl)pyrrolidine-3-carboxamide dihydrochloride
I-18	 * 2HCl *Trans-Rac* *(±)-trans*-4-phenyl-*N*-(quinolin-8-yl)pyrrolidine-3-carboxamide dihydrochloride
I-19	 *Trans-Rac* *(±)-trans*-4-phenyl-*N*-(pyridin-3-yl)pyrrolidine-3-carboxamide dihydrochloride
I-20	 *Trans-Rac* *(±)-trans*-4-phenyl-*N*-[5-(pyridin-3-yl)-1,3-thiazol-2-yl]pyrrolidine-3-carboxamide
I-21	 *Trans-Rac* *(±)-trans*-*N*-(isoquinolin-5-yl)-4-phenylpyrrolidine-3-carboxamide dihydrochloride





Compound No.	Structure
I-22	 * HCl *Trans- Rac* *(±)-trans*-*N*-(biphenyl-3-yl)-4-(thiophen-2-yl)pyrrolidine-3-carboxamide hydrochloride
I-23	 * HCl *Trans- Rac* *(±)-trans*-*N*-(biphenyl-3-yl)-4-(4-fluorophenyl)pyrrolidine-3-carboxamide hydrochloride
I-24	 *Trans-Rac* *(±)-trans*-*N*-(biphenyl-4-yl)-4-phenylpyrrolidine-3-carboxamide hydrochloride
I-25	 *Trans-Rac* *(±)-trans*-4-phenyl-*N*-[4-(pyridin-3-yl)phenyl]pyrrolidine-3-carboxamide dihydrochloride




Compound No.	Structure
I-26	 *Trans-Rac* *(±)-trans-N*-[3-(6-fluoropyridin-3-yl)phenyl]-4-phenylpyrrolidine-3-carboxamide
I-27	 *** HCl** *Trans- Rac* *(±)-trans-N*-(biphenyl-3-yl)-4-(3-fluorophenyl)pyrrolidine-3-carboxamide hydrochloride
I-28	 *** HCl** *Trans- Rac* *(±)-trans-N*-(biphenyl-3-yl)-4-(2-fluorophenyl)pyrrolidine-3-carboxamide hydrochloride
I-29	 (3*R*,4*S*)-*N*-(isoquinolin-5-yl)-4-phenylpyrrolidine-3-carboxamide



Compound No.	Structure
I-30	 (3*R*,4*S*)-*N*-(1-methylisoquinolin-5-yl)-4-phenylpyrrolidine-3-carboxamide dihydrochloride
I-32	 ***2HCl** (3*R*,4*S*)-4-phenyl-*N*-(thieno[2,3-*c*]pyridin-3-yl)pyrrolidine-3-carboxamide dihydrochloride
I-33	 **HCl** (3*R*,4*S*)-*N*-benzyl-4-phenylpyrrolidine-3-carboxamide hydrochloride
I-34	 (3*R*,4*S*)-*N*,4-diphenylpyrrolidine-3-carboxamide



Compound No.	Structure
I-35	 *2HCl (3*R*,4*S*)-*N*-[(1-methylpiperidin-4-yl)methyl]-4-phenylpyrrolidine-3-carboxamide dihydrochloride
I-36	 HCl (3*R*,4*S*)-*N*-[(*1,4-trans*)-4-hydroxycyclohexyl]-4-phenylpyrrolidine-3-carboxamide hydrochloride
I-37	 *HCl (3*R*,4*S*)-*N*-(biphenyl-3-yl)-4-phenylpyrrolidine-3-carboxamide hydrochloride
I-38	 *2HCl (3*R*,4*S*)-*N*-(isoquinolin-3-yl)-4-phenylpyrrolidine-3-carboxamide dihydrochloride

Compound No.	Structure
I-39	 *2HCl (3*R*,4*S*)-4-phenyl-*N*-[4-(pyridin-3-yl)phenyl]pyrrolidine-3-carboxamide dihydrochloride
I-40	 HCl HCl (3*S*,4*R*)-*N*-(isoquinolin-5-yl)-4-phenylpyrrolidine-3-carboxamide dihydrochloride
I-41	 * 2HCl (3*S*,4*R*)-4-phenyl-*N*-[4-(pyridin-3-yl)phenyl]pyrrolidine-3-carboxamide dihydrochloride
I-42	 *HCl (3*S*,4*R*)-*N*-(biphenyl-3-yl)-4-phenylpyrrolidine-3-carboxamide hydrochloride

Compound No.	Structure
I-43	 *2HCl (3*S*,4*R*)-*N*-(isoquinolin-3-yl)-4-phenylpyrrolidine-3-carboxamide dihydrochloride
I-44	 *2HCl (3*R*,4*R*)-*N*-(isoquinolin-5-yl)-4-(thiophen-2-yl)pyrrolidine-3-carboxamide dihydrochloride
I-47	 (±)-trans *(±)-trans*-*N*-methyl-4-phenyl-*N*-[3-(pyridin-3-yl)phenyl]pyrrolidine-3-carboxamide
I-49	 2HCl (±)-trans

Compound No.	Structure
	(±)-trans- (4-phenylpyrrolidin-3-yl)[3-(pyridin-3-yl)azetidin-1-yl]methanone dihydrochloride
I-50	 *2HCl *Trans-Rac* *(±)-trans*-*N*-[3-(pyridin-3-yl)phenyl]-4-(tetrahydro-2*H*-pyran-4-yl)pyrrolidine-3-carboxamide dihydrochloride
I-52	 2HCl (±)-trans *(±)-trans*-*N*-(3-phenoxyphenyl)-4-phenylpyrrolidine-3-carboxamide dihydrochloride
I-53	 3HCl (±)-trans *(±)-trans*-4-phenyl-*N*-[3-(pyrimidin-5-yl)phenyl]pyrrolidine-3-carboxamide triihydrochloride



Compound No.	Structure
I-56	 (3*S*,4*S*)-*N*-(isoquinolin-5-yl)-4-(thiophen-2-yl)pyrrolidine-3-carboxamide
I-57	 *2HCl (3*R*,4*S*)-*N*-(isoquinolin-5-yl)-*N*-methyl-4-phenylpyrrolidine-3-carboxamide dihydrochloride






Compound No.	Structure
I-58	 *2HCl (3*R*,4*R*)-*N*-(isoquinolin-5-yl)-4-(1,3-thiazol-2-yl)pyrrolidine-3-carboxamide dihydrochloride
I-59	 *2HCl (3S,4*S*)-*N*-(isoquinolin-5-yl)-4-(1,3-thiazol-2-yl)pyrrolidine-3-carboxamide dihydrochloride





or

(b) Compound Nos. I-65 to I-72; I-74 to I-76

Compound No.	Structure







Compound No.	Structure
I-65	 *HCl Trans-Rac
I-66	 *2HCl






Compound No.	Structure
I-67	 *2HCl
I-68	 (±)-trans
I-69	 (±)-trans
I-70	 (±)-trans
I-71	






Compound No.	Structure
	(±)-trans
I-72	 (±)-trans
I-74	
I-75	
I-76	






and







(c) Compound Nos. I-81 to I-100; I-103 to I-123








Compound No.	Structure
I-81	 2HCl
I-82	 2HCl
I-83	 2HCl
I-84	 HCl
I-85	 HCl (±)-trans
I-86	 HCl (±)-trans







Compound No.	Structure
I-87	 HCl
I-88	 2HCl
I-89	 HCl (±)-trans
I-90	 HCl (±)-trans
I-91	 HCl (±)-trans


Compound No.	Structure
I-92	 (±)-trans
I-93	 (±)-trans
I-94	 (±)-trans
I-95	
I-96	

Compound No.	Structure
I-97	 (±)-trans
I-98	 (±)-trans
I-99	 (±)-trans
I-100	 (±)-trans
I-103	

Compound No.	Structure
I-104	 2HCl (±)-trans
I-105	 2HCl (±)-trans
I-106	 2HCl (±)-trans
I-107	 2HCl (±)-trans
I-108	 2HCl
I-109	 HCl

Compound No.	Structure
I-110	 HCl
I-111	 HCl
I-112	 HCl
I-113	 HCl
I-114	 HCl
I-115	 HCl
I-116	 2HCl

Compound No.	Structure
I-117	 HCl
I-118	 TFA
I-119	 2HCl
I-120	 2HCl
I-121	 HCl
I-122	 HCl

Compound No.	Structure
I-123	 HCl

Claim 15. A pharmaceutical composition, comprising the compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt or tautomer thereof, and a pharmaceutically acceptable excipient.

Claim 16. Use of the compound of any one of claims 1-14, or a pharmaceutically acceptable salt or tautomer thereof, or the pharmaceutical composition of claim 15 in the manufacture of a medicament for treating or reducing the effect of a disease or disorder associated with NR2F6 modulation in a subject, wherein the disease or disorder is at least one selected from the group consisting of autoimmune disease, cancer, and haematological malignancy, wherein an effective amount of the compound, pharmaceutically acceptable salt, tautomer thereof or the pharmaceutical composition is to be administered to the subject.

Claim 17. The use according to claim 16, wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosiss (lupus), inflammatory bowel disease, multiple sclerosis, type-1 diabetes mellitus, Guillian-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, psoriasis/psoriatic arthritis, Grave's disease, Hashimoto's thyroiditis, myasthenia gravis, and vasculitis.

Claim 18. The use according to claim 16, wherein the cancer is a solid tumor selected from the group consisting of adenocarcinoma of the lung, bile duct cancer, bladder cancer; bone cancer, brain tumor, glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, adult anaplastic astrocytoma; benign prostate hyperplasia bronchoalveolar carcinoma, breast cancer, including metastatic breast cancer; cervical cancer, cholangiocarcinoma, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, squamous cell carcinoma of the head and neck, gallbladder cancer hepatocellular cancer, kidney cancer, liver cancer, lung cancer, melanoma; neuroendocrine cancer, metastatic neuroendocrine tumor, non-small cell lung cancer (NSCLC), small cell lung cancer, ovarian cancer, primary peritoneal cancer, pancreatic cancer, prostate cancer, including androgen-dependent and androgen-independent prostate cancer, colorectal carcinoma, renal cancer, metastatic renal cell carcinoma, soft tissue sarcoma, urinary bladder cancer, and uterine cancer.

Claim 19. The use of claim 16, wherein the hematologic malignancy is selected from the group consisting of acute myeloid leukemia, chronic myelogenous leukemia (CML),

accelerated CML, CML blast phase (CML-BP), acute lymphoblastic leukemia, chronic lymphocytic leukemia (CLL), Hodgkin's disease, non-Hodgkin's lymphoma, follicular lymphoma, mantle cell lymphoma, B-cell lymphoma, T-cell lymphoma, multiple myeloma, Waldenstrom's macroglobulinemia, myelodysplastic syndromes (MDS), refractory anemia (RA), RA with ringed sideroblasts, RA with excess blasts (RAEB), RAEB in transformation, and a myeloproliferative syndrome.

Claim 20. Use of the compound of any one of claims 1-14, or a pharmaceutically acceptable salt or tautomer thereof, or the pharmaceutical composition of claim 15 in the manufacture of a medicament for treating or reducing the effect of a gastrointestinal disease or disorder in a subject, wherein an effective amount of the compound, pharmaceutically acceptable salt, tautomer thereof or the pharmaceutical composition is to be administered to the subject.

Claim 21. The use of claim 20, wherein the gastrointestinal disorder is IBD, Crohn’s disease, or colitis.

Claim 22. Use of the compound of any one of claims 1-14, or a pharmaceutically acceptable salt or tautomer thereof, or the pharmaceutical composition of claim 15 in the manufacture of a medicament for treating a condition associated with hepatic steatosis in a subject, wherein an effective amount of the compound, pharmaceutically acceptable salt, tautomer thereof or the pharmaceutical composition is to be administered to the subject.

Claim 23. The use of claim 22, wherein the condition associated with hepatic steatosis is non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).

Claim 24. A compound of any one of claims 1-14, or a pharmaceutically acceptable salt or tautomer thereof, or the pharmaceutical composition of claim 15 for use in treating or reducing the effect of a disease or disorder associated with NR2F6 modulation, wherein the disease or disorder is at least one selected from the group consisting of autoimmune disease, cancer, haematological malignancy, gastrointestinal disorder, and non-alcoholic fatty liver disease (NAFLD).

Claim 25. A compound of any one of claims 1-14, or a pharmaceutically acceptable salt or tautomer thereof, or the pharmaceutical composition of claim 15 for use in therapy.